Sort
21,453 grants matching “tuberculosis”
Development of Gleevec for TB and TB/HIV
$600,000Daniel Kalman · Emory University · UH2 · FY2015 · AI
EAP-DERIVED MONOCLONAL ANTIBODIES FOR PHENOTYPING GUINEA PIG IMMUNE CELLS.
$600,000Mark Geisberg · Silver Lake Research Corporation · N43 · FY2020 · AI
CONST OF ANIMAL FACIL: TUBERCULOSIS
$600,000University Of Texas Hlth Sci Ctr Houston · C06 · FY2002 · RR
Development of Gleevec for TB and TB/HIV
$599,999Daniel Kalman · Emory University · UH2 · FY2016 · AI
Targeting trained immunity and Th1/Th17 axis with combination adjuvants
$599,999Shabaana A. Khader · University Of Chicago · U01 · FY2023 · AI
B-SMART - Broadly neutralizing antibodies for SaRNA Mediated Antiviral Response Therapy
$599,989Mark Lee Harlow · Lynntech, Inc. · N43 · FY2025 · AI
Inhaled Delivery of Clofazimine - A High Efficiency, Flow Independent, Targeted, Low Cost DPI
$599,924John Koleng · Via Therapeutics, Llc · N01 · FY2018 · AI
Comparative Effectiveness/Implementation of TB Case Finding in Rural South Africa
$599,898David Wesley Dowdy · Johns Hopkins University · R01 · FY2016 · AI
PROJECT 1: Identification of host and bacterial pathways that control tuberculosis pathogenesis in humans
$599,844Jeffery S Cox · University Of California, San Francisco · U19 · FY2024 · AI
Detecting pathogen and host factors on extracellular vesicles for pediatric TB diagnosis and management
$599,830Tony Y. Hu · Tulane University Of Louisiana · R01 · FY2024 · HD
Center for Native Oral Health Research (CNOHR)
$599,820Judith E.n. Albino · University Of Colorado Denver · U54 · FY2009 · DE
Statins as Adjunctive, Host-Directed Therapy for TB
$599,710Petros C Karakousis · Johns Hopkins University · UH2 · FY2015 · AI
Clinical Core
$599,707Neel Rajnikant Gandhi · Emory University · U19 · FY2016 · AI
Novel Murine Studies for Optimizing Effective Short-Course TB Therapy
$599,656Arnold Louie · University Of Florida · P01 · FY2016 · AI
ARKANSAS TUBERCULOSIS CONTROL PROGRAM
$599,581Naveen Patil · Arkansas State Department Of Health · U52 · FY2012 · PS
Therapeutic vaccine platform to boost immune responses in Tuberculosis
$599,471Karen G. Anthony · L2 Diagnostics, Llc · N43 · FY2025 · AI
GENETIC FACTORS AND SUSCEPTIBILITY TO TUBERCULOSIS
$599,399Immune Disease Institute, Inc. · R01 · FY2003 · HL
Tuberculosis epidemiology and novel transmission routes in rural Tanzania
$599,389Philip C Hopewell · University Of California, San Francisco · U01 · FY2012 · AI
BIODIVERSITY CONSERVATION AND DRUG DISCOVERY IN MADAGASCAR
$599,386David G Kingston · Virginia Polytechnic Inst And St Univ · U01 · FY2008 · TW
Exploring the metabolism of non-replicating and drug-resistant TB
$599,050Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Development Of New Chemotherapeutics For Tuberculosis
$599,050Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Experimental Animal Models of TB: Chemotherapeutics and Imaging
$599,050Clifton Barry · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Manipulation of the host cell inflammasome by Mycobacterium tuberculosis
$599,019Volker Briken · Univ Of Maryland, College Park · R01 · FY2022 · AI
Optimizing vaccine science to improve the outcome of tuberculosis treatment
$598,840Selvakumar Subbian · Rbhs-New Jersey Medical School · R01 · FY2021 · AI
Mobile Health for Implementation of Home-based TB Contact Investigation in Uganda
$598,779John Lucian Davis · Yale University · R01 · FY2015 · AI